BioSpace News Archive

Soleno Therapeutics, Inc. (Nasdaq:SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the pricing of the underwritten public offering of 30,303,030 shares of its common stock at a public offering price of $1.65. Soleno has also granted the underwriters a 30-day option to purchase up to 4,545,454 additional shares of common stock, a

Intends to seek full marketing authorization for Oxbryta to treat hemolytic anemia in sickle cell disease Marketing Authorization Application submission planned by mid-2021 SOUTH SAN FRANCISCO, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Oxbryta ® (voxelotor) tablets to treat hemolytic anemia in sickle cell dis

Singer/songwriter Crystal Bowersox kicks off the educational initiative by encouraging people to educate their support network and develop a plan for low blood sugar and very low blood sugar emergencies

Dr. Garite will support clinical development and operations as Sera transitions from clinical to commercial-stage company -

Indivior PLC (LON: INDV) announces new data from the two-year analysis of the 24-month real-world observational study, RECOVER™ (Remission from Chronic Opioid Use—Studying Environmental and SocioEconomic Factors on Recovery

NeuroSigma, Inc., a Los Angeles-based bioelectronics company focused on commercializing Trigeminal Nerve Stimulation (TNS) technology for treating neurological and neuropsychiatric disorders today announced that results from a randomized controlled trial of external Trigeminal Nerve Stimulation (eTNS®) for treating drug resistant epilepsy (DRE) were published in the June 2020 issue of the journal Brain Stimulation.

Analysis of treatment outcomes in five severe COVID-19 patients showed substantial benefit to patients treated with opaganib under compassionate use in both clinical outcomes and inflammatory markers as compared to a matched case-control group from the same hospital

Quest Products, LLLC. (Quest) today announced its acquisition of Summit Pharmaceuticals / Alliance Labs. Quest is a portfolio company of Promus Equity Partners (Promus).

More fluorescent labels launched at one time than in the past 2 decades, a new dimension in cell analysis, and new reagents for high resolution biology

The KD Pharma Group SA (“KD Pharma”), a global pharmaceutical CMO and one of the leading producers of Omega-3 fatty acids, and Herbolea Biotech Srl (“Herbolea”), an Italian biotechnology company developing proprietary botanical extraction technologies, are pleased to announce the signing of a Licensing Agreement granting KD Pharma th